On August 24, 2026, Erasca, Inc. announced that the U.S. Food and Drug Administration granted Fast Track Designation to ERAS-0015 for treating metastatic pancreatic adenocarcinoma. This designation facilitates development and may expedite review through benefits such as accelerated approval, priority review, and rolling review, though it does not guarantee marketing approval or change regulatory standards. The company plans to initiate a phase 3 clinical trial in pancreatic cancer and potentially registration-enabling trials in lung cancer. Erasca, Inc. operates in the biotechnology industry, developing targeted therapies for oncology.

Erasca, Inc. reported financial results for the quarter ended June 30, 2026, posting a net loss of $44.1 million, or $(0.14) per share, compared to a $33.9 million loss in the prior year period. Research and development expenses increased to $35.9 million from $21.2 million, driven by clinical trial costs and personnel expenses. The company holds $384.3 million in cash and marketable securities as of June 30, 2026. Erasca also announced updated clinical data for its lead candidate ERAS-0015, showing a 57% unconfirmed overall response rate in second-line KRAS G12X pancreatic cancer, and highlighted the completion of an upsized public offering that raised approximately $632.5 million in July 2026 to strengthen its balance sheet. Erasca is a clinical-stage precision oncology company focused on discovering and developing therapies for RAS/MAPK pathway-driven cancers.

Erasca, Inc. appointed Charles S. Fuchs as President of Research & Development effective August 10, 2026. Dr. Fuchs brings over three decades of oncology leadership experience from roles at Genentech/Roche and Tubulis GmbH. His compensation package includes a $570,000 annual base salary, a target bonus equal to 45% of base, and a stock option award for 1,300,000 shares vesting over four years. To facilitate this hire, the Board adopted the 2026 Employment Inducement Incentive Award Plan, reserving 6,200,000 additional shares without prior stockholder approval under Nasdaq rules. Erasca operates in the biotechnology industry, focusing on gene editing therapies for genetic diseases.

Erasca, Inc. entered into an underwriting agreement with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Jefferies LLC, and Evercore Group L.L.C. to issue and sell 31,428,572 shares of common stock at a public offering price of $17.50 per share. The underwriters will purchase the shares from the company at $16.45 per share, and the company has granted a 30-day option for the underwriters to purchase an additional 4,714,285 shares. Net proceeds are expected to be approximately $516.0 million, or approximately $593.5 million if the option is exercised in full. Erasca, Inc. is a biotechnology company focused on developing oncology-related therapies.

Erasca, Inc. announced updated preliminary Phase 1 data for its pan-RAS molecular glue ERAS-0015 from the AURORAS-1 trial, showing a 57% uORR 8wk in KRAS G12X pancreatic ductal adenocarcinoma patients at a 32 mg QD dose. The company plans to initiate potentially registration-enabling trials in non-small-cell lung cancer in the first half of 2027 and Phase 3 pivotal trials in pancreatic ductal adenocarcinoma and RAS-mutant NSCLC in 2027 or 2028. Erasca, Inc. is a biotechnology company focused on the discovery and development of product candidates that shut down the RAS/MAPK pathway.